Nicox (OTCMKTS:NICXF) & Tvardi Therapeutics (NASDAQ:TVRD) Financial Review

Nicox (OTCMKTS:NICXF) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility & Risk

Nicox has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Profitability

This table compares Nicox and Tvardi Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nicox	N/A	N/A	N/A
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Nicox and Tvardi Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nicox	0	1	1	0	2.50
Tvardi Therapeutics	1	3	3	1	2.50

Tvardi Therapeutics has a consensus target price of $39.80, indicating a potential upside of 1,407.58%. Given Tvardi Therapeutics’ higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Nicox.

Valuation & Earnings

This table compares Nicox and Tvardi Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nicox	$3.59 million	5.76	-$24.23 million	N/A	N/A
Tvardi Therapeutics	$7.14 million	3.47	-$18.21 million	($3.10)	-0.85

Tvardi Therapeutics has higher revenue and earnings than Nicox.

Institutional and Insider Ownership

44.7% of Tvardi Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Tvardi Therapeutics beats Nicox on 8 of the 11 factors compared between the two stocks.

About Nicox

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.